SWAP: Adding or Switching to PegIFN Improves Response in Patients With Chronic Hepatitis B on Long-Term NA Therapy

November 8-12, 2019; Boston, Massachusetts
Patients on stable nucleos(t)ide analogue therapy who added or switched to pegIFN had significantly better HBeAg loss rates and HBsAg level reductions compared with patients who continued nucleos(t)ide analogue therapy alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 186 KB
Released: November 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Stefan Zeuzem, MD Released: July 22, 2021

Robert Gish on cure strategies at EASL 2021: si RNAs, JNJ-3989, AB-729, GSK3228836, VIR-3434, c-PAMs or capsid inhibitors, AB-836, and more from Clinical Care Options (CCO)

Robert G. Gish, MD Released: July 22, 2021

Commentary from Nancy Reau on HDV and HBV

Nancy Reau, MD Released: July 22, 2021

Top EASL 2021 studies from Clinical Care Options (CCO) and Tarik Asselah: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Tarik Asselah, MD, PhD Released: July 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue